VIRTUAL EVENT
The Endpoint Dilemma in Obesity Medicine:
Weight, health, and what comes next
RETHINKING OUTCOME MEASUREMENT IN OBESITY TRIALS
Semaglutide's approval in 2021 changed what obesity treatment could achieve. In 2026, the field is still debating whether our outcome measures are keeping pace.
As next-generation agents deliver 20-25% total body weight loss, the question is no longer whether we can move the scale — it's whether we're measuring the right things when we do. How do we balance regulatory weight endpoints against the imperative to demonstrate broader health benefit? Who decides what counts?
Join this live expert panel for a provocative discussion on the paradigm shift from weight-centric to health-centric outcome measurement in obesity clinical trials.
GAIN ACTIONABLE INSIGHTS INTO:
Why BMI-based eligibility criteria and weight-based endpoints may no longer be sufficient to differentiate new AOMs in a crowded market.
The muscle mass question: with 25-40% of weight lost on GLP-1/dual agonist therapy being lean mass, should preservation become a regulatory requirement?
What it would take for wearable-derived endpoints (activity, sleep architecture, sedentary behavior) to serve as primary or key secondary endpoints, and who bears the burden of proof.
Lessons from SELECT: if cardiovascular benefit is partially weight-independent, should MACE be elevated to a co-primary endpoint in future registration trials?
What one new endpoint category panelists would mandate for all Phase III obesity trials starting today, and why
MEET THE PANEL
Professor Ildiko Lingvay
200+ publications; participant in nearly 100 clinical trials
Board certified in obesity medicine, endocrinology, diabetes & metabolism
Medical Director, Office of Clinical Trials Management, UT Southwestern
READ BIO
Dr Ildiko Lingvay is Tenured Professor of Medicine in the Division of Endocrinology and Professor in the Peter O’Donnel Jr. School of Public Health at University of Texas Southwestern Medical Center (UT Southwestern) in Dallas, TX, USA. Dr Lingvay is the Medical Director of the Office of Clinical Trials Management, overseeing the institutional approval of all clinical trials at UT Southwestern. She is board certified in obesity medicine as well as endocrinology, diabetes and metabolism.
Professor Mark Petrie
410+ publications and 40+ Clinical EventsDeputy Editor, European Journal of Heart Failure
Board member, Heart Failure Association European Society of Cardiology
READ BIO
Prof. Petrie is Professor of Cardiology in the School of Cardiovascular and Metabolic Health at the University of Glasgow, and a cardiologist at Glasgow Royal Infirmary, UK. Prof. Petrie has a high-volume clinical practice within a large heart failure team. Prof. Petrie worked as an interventional and heart failure/transplant cardiologist for many years before transitioning to an academic post.
Graham Ellis, MD
25+ years in diabetes, endocrinology, and metabolic disease
Principal Investigator on 150+ international Phase 2–4 trials
Founding member of the Centre for Diabetes and Endocrinology (CDE)
READ BIO
Dr. Graham C Ellis, MD, is Clinical Vice President at Signant Health. A specialist physician with more than 25 years of experience in diabetes, endocrinology, and metabolic disease, he has served as Principal Investigator on more than 150 international clinical trials. Dr. Ellis previously served as Executive Director of Medical Science and Strategy at PPD, the clinical research business of Thermo Fisher Scientific, and is a founding member of the Centre for Diabetes and Endocrinology (CDE).
Dr Elias Ketiar
20+ years in General Internal Medicine and CardiologyMember of the Royal College of Physicians (London)
Expertise in clinical trial design, execution, and governance
READ BIO
Dr. Elias Ketiar serves as the Clinical Vice President, Science & Medicine, at Signant Health. Dr. Ketiar draws on his wealth of more than 20 years of academic and clinical experience to advise on clinical trial design, execution, and governance.
WHY ATTEND
Whether you're designing a next-generation AOM trial, evaluating how your endpoint strategy holds up against a shifting regulatory and competitive landscape, or working through what health-centric outcome measurement looks like in practice, this panel brings together the academic rigor and industry experience to give you answers you can act on.
WHO IS SIGNANT HEALTH
Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant’s comprehensive eClinical solutions. Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.